Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroRegen Scaffold with BMMCs or MSCs for Chronic Spinal Cord Injury
NCT02352077Phase 1Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Jan 2015
- Primary completion
- Dec 2021
- Modality
- Device-based Delivery, Recombinant Proteins and Enzymes, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NeuroRegen Scaffold, bone marrow mononuclear cells and mesenchymal stem cells in spinal cord injury (SCI), sponsored by Chinese Academy of Sciences. Primary endpoint: Number of patients with adverse events at 6 months. Status: unknown.
02
Drugs
NeuroRegen Scaffoldbone marrow mononuclear cellsmesenchymal stem cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02352077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352077.